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Abstract  
Thrombocytosis is a frequently seen condition during childhood. While it usually develops secondarily due to reasons such as infection or anemia, it 
may rarely develop due to clonal causes. Thrombocytosis becomes a life-threatening condition by causing severe complications such as hemorrhage 
and thrombosis development. Treatment is not recommended in patients who are asymptomatic and with a platelet count below 1,500,000/mm3, 
however, treatment is required in cases who are symptomatic and with a platelet count above 1,500,000/mm3 in conditions such as primary 
thrombocytosis. This article present the outcomes of a patient who was treated using low-dose hydroxyurea when he developed severe 
thrombocytosis after splenectomy. 
 
 
Pan African Medical Journal. 2019;32:175. doi:10.11604/pamj.2019.32.175.17841 
This article is available online at: http://www.panafrican-med-journal.com/content/article/32/175/full/ 
 
© Hakan Sarbay et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution 
















Pan African Medical Journal – ISSN: 1937- 8688   (www.panafrican-med-journal.com) 








Thrombocytosis is one of the common hematological findings seen 
during childhood. The most common causes include infections, 
anemia, autoimmune diseases and splenectomy [1]. Rarely, 
thrombocytosis may also develop due to clonal causes. The most 
prominent examples of this include chronic myeloid leukemia and 
essential thrombocytosis [2]. The first step to approach 
thrombocytosis is to repeat the complete blood count test to rule out 
the false high values caused by cellular destruction. When 
thrombocytosis is confirmed, it is necessary to classify the 
thrombocytosis based on its severity. Studies have divided 
thrombocytosis into four groups based on the risk of complication 
development: mild thrombocytosis (500,000-700,000/mm3), 
moderate thrombocytosis (700,000-900,000/mm3), severe 
thrombocytosis (>900,000/mm3) and very severe thrombocytosis 
(>1,000,000/mm3) [3, 4]. This article present the outcomes of a 
patient who was treated using low-dose hydroxyurea when he 
developed severe thrombocytosis after splenectomy. 
  
  
Patient and observation 
 
Fifteen-year-old male patient who underwent splenectomy 5 years 
ago due to hereditary spherocytosis, massive splenomegaly and 
hypersplenism applied for outpatient clinic visit. Having no complaints 
other than fatigue and intermittent abdominal pain, the patient was 
receiving penicillin prophylaxis and acetylsalicylic acid (100mg/day) 
treatment. Laboratory results included a white blood cell count of 
18.760/uL, hemoglobin of 12.7gr/dL, platelet count of 2,235,000/uL, 
ferritin of 68ng/mL, Vitamin B12 of 262ng/mL and folate of 6.1ng/mL 
and liver and kidney functions tests were within normal limits. The 
patient was hospitalized for IV hydration therapy. Acetylsalicylic acid 
treatment was continued. Peripheral smear leukocyte formula 
included neutrophil of 58%, lymphocyte of 36%, monocyte of 4% and 
eosinophil of 2%. No atypical cell or blast was observed. Mild 
hypochromia, microspherocytes and large clusters of platelets were 
observed. In the follow-up analyses after hydration therapy, platelet 
counts were above 2,000,000/uL. Analysis for Janus kinase (JAK) 
mutation was sent. Hydroxyurea was initiated at a dose of 
1x500mg/day (10mg/kg/day). Platelet count regressed to 
1.630.000/uL at week 2 and to 1,568,000/uL at week 4. Experiencing 
no clinical or laboratory side effect in the weekly follow-ups, the 
patient had a platelet count of 1,440,000/uL at the end of week 6 
(Table 1). Hydroxyurea dose was increased to 15mg/kg/day. As the 
patient developed dyspeptic complaints, the dose of the medication 






Pathophysiologically, thrombocytosis is divided into two groups as 
primary and secondary. Primary causes include essential 
thrombocytosis and familial thrombocytosis. As with other 
myeloproliferative diseases, essential thrombocytosis is more common 
in adult age groups and rarely seen during childhood. Secondary 
thrombocytosis is more common during infancy and its incidence 
decreases with increasing age [5, 6]. While the patient's 
thrombocytosis has been considered to be due to splenectomy, Janus 
kinase 2 (JAK2) mutation was studied to rule out essential 
thrombocytosis. While thrombocytosis is mostly asymptomatic, high 
platelet count may cause symptoms and signs such as headache called 
vasomotor phenomenon, visual disturbances, fatigue, chest pain, 
abdominal pain, vertigo, aphasia and dysarthria independent from the 
etiological causes [5]. Our case had the complaints of fatigue and 
intermittent abdominal pain. Platelet count was above 
2,000,000/mm3 and taking the splenectomy into account, the risk of 
thrombosis was considered to be high. The most important point in 
the follow-up and treatment of thrombocytosis is to determine the 
etiology. In conditions such as infection, anemia and inflammatory 
diseases, thrombocytosis regresses when the underlying condition is 
treated [6]. However, thrombocytosis may be more resistant after 
splenectomy. Therefore, longer treatment may be required compared 
to the other etiological conditions. The most commonly used 
medication in treatment is acetylsalicylic acid. Thromboxane causes a 
decrease in platelet activity by suppressing A2 production [3]. Our 
patient has been receiving acetylsalicylic acid treatment for almost 5 
years. Thrombosis was not observed despite platelet counts were high 
in follow-up analyses. However, due to high platelet count, 
hydroxyurea treatment was planned to be initiated. In the literature, 
cytoreductive therapy has been mostly initiated in essential 
thrombocytosis and when the platelet count is 
>1,500,000/mm3 [7, 8]. It is recommended to start the treatment at 
a dose of 15mg/kg/day and adjust the dose based on follow-up. While 
there is a risk of leukemic transformation at long term, it was found 
to be well-tolerated, effective in reducing the platelet count and 
reduce the risk of thrombotic events [9, 10]. In our case, hydroxyurea 
was initiated at a dose of 10mg/kg/day. During the follow-up, the 
platelet count regressed below 1,500,000/mm3 and no side effect was 
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observed. The dose was increased to 15mg/kg/day. However, as 
dyspeptic complaints developed after dose increase, the dose was 





There are case reports of successful use of hydroxyurea in patients 
with essential thrombocytosis in the literature [7, 8]. We emphasize 
that in patients with secondary thrombocytosis, low-dose hydroxyurea 
treatment can be used safely when the platelet count is above 
1,500,000/mm3 for a long period of time and the risk of thrombosis is 
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 Table 1: laboratory values of the patient 
  1. Day 1. Week 2. Week 4. Week 5. Week 6. Week 
Plt 2,010,000/uL 1,596,000/uL 1,630,000/uL 1,568,000/uL 1,474,000/uL 1,440,000/uL 
WBC 12,790/Ul 17,660/uL 18,280/uL 11,780/uL 12,390/uL 12,450/uL 
Neut 6,110/Ul 10,570/uL 9,250/uL 5,640/uL 4,890/uL 6,290/uL 
Hgb 10.8 g/dl 11.7 g/dl 11.8 g/dl 12.2 g/dl 12.4 g/dl 11.9 g/dl 
RBC 5.1x106/uL 5.3x106/uL 5.5x106/uL 5.6x106/uL 5.7x106/uL 5,5x106/uL 
Urea 19 mg/dl 13 mg/dl 21 mg/dl 12 mg/dl 8 mg/dl 23 mg/dl 
Creat 0.5 mg/dl 0.6 mg/dl 0.6 mg/dl 0.6 mg/dl 0.7 mg/dl 0.5 mg/dl 
AST 35 U/L 56 U/L 39 U/L 47 U/L 59 U/L 25 U/L 
ALT 16 U/L 31 U/L 22 U/L 31 U/L 30 U/L 28 U/L 
Uric asid 3.7 mg/dl - 4.2 mg/dl - 4.2 mg/dl 4 mg/dl 
Glucose 89 mg/dl - - 89 mg/dl 87 mg/dl 96 mg/dl 
Adverse 
Reaction - - - - - - 
Plt: Platelet, WBC: White blood cell, Neut: Neutrophil, Hgb: Hemoglobin, RBC: Red blood cell,  Creat: Creatinine, AST: Aspartate 
aminotransferase, ALT: Alanine aminotransferase 
